Purolite Ltd revealed on Thursday that it will supply its Praesto Jetted A50, an agarose-based Protein A chromatography resin, for use as part of the commercial manufacturing process of an FDA-approved monoclonal antibody treatment by a contract manufacturing organisation.

Praesto resins are an integral technology used by biopharmaceutical developers for the purification of modern medicines for the treatment of cancer, rheumatoid arthritis, dementia and diabetes.

Launched in April 2018, Praesto Jetted A50 is the company's "best-in-class" Protein A chromatography resin, utilising a patented "Jetting" manufacturing technology for uniform resin beads, a highly desirable characteristic for chromatographic applications.

Purolite is a manufacturer of resin-based separation, purification and extraction technologies.